Vir Biotechnology (VIR) Expected to Announce Quarterly Earnings on Wednesday

Vir Biotechnology (NASDAQ:VIR) is expected to post its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Vir Biotechnology to post earnings of ($0.01) per share and revenue of $55.4890 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.11. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The company had revenue of $64.07 million during the quarter, compared to analysts’ expectations of $19.91 million. During the same quarter in the prior year, the company earned ($0.76) EPS. Vir Biotechnology’s revenue was up 417.8% compared to the same quarter last year. On average, analysts expect Vir Biotechnology to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Vir Biotechnology Stock Performance

NASDAQ:VIR opened at $10.28 on Wednesday. Vir Biotechnology has a one year low of $4.16 and a one year high of $11.66. The stock has a market cap of $1.66 billion, a PE ratio of -3.25 and a beta of 1.66. The stock has a 50 day moving average price of $9.41 and a 200 day moving average price of $7.41.

Insider Buying and Selling

In other news, EVP Verneuil Vanina De sold 13,700 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $9.82, for a total transaction of $134,534.00. Following the completion of the sale, the executive vice president owned 112,982 shares in the company, valued at approximately $1,109,483.24. The trade was a 10.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CAO Brent Sabatini sold 7,711 shares of the business’s stock in a transaction on Monday, March 23rd. The shares were sold at an average price of $9.12, for a total transaction of $70,324.32. Following the completion of the sale, the chief accounting officer directly owned 61,902 shares of the company’s stock, valued at approximately $564,546.24. This trade represents a 11.08% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 257,816 shares of company stock worth $2,326,218 in the last quarter. Company insiders own 16.00% of the company’s stock.

Institutional Trading of Vir Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in VIR. AQR Capital Management LLC grew its stake in Vir Biotechnology by 2,088.4% during the 1st quarter. AQR Capital Management LLC now owns 268,297 shares of the company’s stock worth $1,739,000 after buying an additional 256,037 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Vir Biotechnology in the first quarter valued at approximately $359,000. Goldman Sachs Group Inc. grew its position in shares of Vir Biotechnology by 43.6% during the first quarter. Goldman Sachs Group Inc. now owns 742,674 shares of the company’s stock worth $4,813,000 after acquiring an additional 225,544 shares during the last quarter. Woodline Partners LP increased its holdings in shares of Vir Biotechnology by 245.6% in the 1st quarter. Woodline Partners LP now owns 466,737 shares of the company’s stock valued at $3,024,000 after acquiring an additional 331,701 shares during the period. Finally, Focus Partners Wealth raised its position in Vir Biotechnology by 15.3% in the 1st quarter. Focus Partners Wealth now owns 19,317 shares of the company’s stock valued at $125,000 after purchasing an additional 2,566 shares during the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Leerink Partners reaffirmed an “outperform” rating and issued a $20.00 price target on shares of Vir Biotechnology in a research note on Thursday, February 26th. Raymond James Financial raised Vir Biotechnology from an “outperform” rating to a “strong-buy” rating and set a $19.00 price objective for the company in a research report on Tuesday, February 24th. HC Wainwright boosted their price objective on shares of Vir Biotechnology from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, March 4th. Barclays increased their target price on shares of Vir Biotechnology from $26.00 to $30.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 24th. Finally, Evercore reiterated an “outperform” rating and set a $18.00 price target on shares of Vir Biotechnology in a research report on Tuesday, February 24th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.38.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc is a clinical?stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell?based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID?19, HIV, hepatitis B, and tuberculosis.